Abstract OBJECTIVE: The aim of the study was to examine the long-term health-related quality of life following surgery for lung cancer.
INTRODUCTION
The long-term changes in quality of life after lung cancer surgery needs further investigation.
Studies have shown that patients want information regarding the risk of experiencing a significant reduction in their quality of life [1] in addition to details concerning postoperative complications. Recent prospective studies regarding health-related quality of life after lung cancer surgery provide important information concerning post-operative changes but concentrate on the first year after surgery [2] [3] [4] [5] [6] [7] . However, less is known regarding the long-term impact of lung cancer surgery on patients' perception of quality of life beyond the first year after surgery. Objective functional measures such as tests of lung function or exercise capacity do not adequately predict long-term quality of life [8] .
To gain further knowledge in this area, it is consequently necessary to use a validated instrument designed for quality-of-life assessment.
We performed a prospective population-based cohort study to explore health-related quality of life at baseline, 6 months, and 2 years after lung surgery. mail. Those who did not respond were sent up to two reminders after 1 and 2 months, respectively. Two years after the operation, a second SF-36 questionnaire was mailed to the patients who had answered the 6-month questionnaire. Those who did not respond to the third questionnaire were sent a reminder after 1 month. Those who still had not responded after this first reminder were contacted by phone and asked to respond to the questionnaire.
Quality-of-life instrument
The SF-36 (Swedish version) is a standardized, self-administered survey measuring health-related quality of life [9, 10] . In all scales, higher score indicates better health. Several advantages of the physical component summary (PCS) and mental component summary (MCS) scores over the original eight scales of the SF-36 have been reported [9, 11] ; however, the summary scores should always be interpreted in combination with the subscale scores [12] . The SF-36 questionnaire has been accepted as valid and responsive to changes in health-related quality of life after lung cancer surgery [13] .
Survival
Survival was ascertained in May 2010 using the Swedish personal identity number and the continuously updated national total population register. 
Statistical analyses

RESULTS
Study population and response rate
Of the 249 patients who preoperatively completed the SF-36 questionnaire, 40 died during the 2-year follow-up and 43 patients were excluded from the study because they, for whatever reason, did not complete either the 6-month questionnaire or the 2-year follow-up questionnaire. The response rate at 6 months was 85% and, at 2 years of follow-up, was 95%. The 166 patients who returned both the 6-month and the 2-year questionnaire were included in our study. Enrollment and follow-up rate is shown in Fig. 1 .
The characteristics of the study population are presented in Table 1 .
Operation type, postoperative data, tumor stage, and histopathology are shown in Table 2 . Eight patients underwent video-assisted thoracoscopic surgery. All other patients had a Ischemic heart disease was defined as a history of angina pectoris, myocardial infarction, or revascularization procedure (coronary artery bypass surgery or percutaneous coronary intervention). Hypertension was defined as a history of high blood pressure requiring medication. Congestive heart disease was defined as a history of heart failure or left ventricular ejection fraction less than 0.5. Diabetes mellitus was defined as diabetes requiring insulin or oral anti-diabetics. Peripheral vascular disease was defined as a history of claudication, carotid stenosis or abdominal aneurysm. Cerebrovascular disease was defined as a history of stroke or transient ischemic attack.
Smoking status was divided into three categories: current, former and never smoker. Current smoker was defined as an active smoker or a person who had stopped smoking within 1 year of surgery. Former smoker was defined as a previous smoker who had stopped smoking more than 1 year before surgery. Never smoker was defined as a person who had never been an active smoker.
muscle-sparing posterolateral thoracotomy. Post-operative management included thoracic epidural analgesia. The study population and the nonresponders were similar in most of the characteristics except for a higher proportion of lobectomies (72.3% vs 57.8%, p = 0.031) and a higher mean age (65.2 vs 61.0, p = 0.012) in the study group (Table 3) . Adjuvant chemotherapy was more common among nonresponders (23.5% vs 38.6%, p = 0.017).
Survival
Survival (249 patients) at 1 year was 89% (222 at risk), at 2 years 83% (206 at risk), at 3 years 79% (120 at risk), and at 4 years 73% (22 at risk). The mean follow-up time was 3.19 (standard deviation 0.58) years.
Quality of life
SF-36 scores before, and 6 months and 2 years after lung surgery compared to an age-and gender-matched reference population are shown in Table 4 .
Physical and mental summary scores. The PCS score dropped significantly ( p < 0.001) from 47.4 (10.3) at baseline to 41.1 (10.5) at 6 months and remained at the same level at 2-year follow-up (41.4 (11.6)). The PCS score of the study population 2 years after surgery was inferior to an age-and gender-matched reference population (44.0 (3.9)) ( p = 0.013).
The MCS score increased significantly from 40.5 (13.8) at baseline to 44.6 (12.6) at 6 months ( p = 0.001) and further improved to 46.9 (12.2) at 2 years ( p = 0.005). Despite a steady improvement, the MCS score did not reach the level of the reference population (50.6 (1.7)) ( p = 0.01).
SF-36 subscales. Although most changes in the mean SF-36 subscale scores were statistically significant, a clinically relevant change, defined as 10 score points or more, was noted only in two of the eight subscales: mental health (MH) and physical role functioning (RP).
The MH subscale improved slightly during the first 6 months All variables are reported as n (%), except for age, which is reported as mean (standard deviation). a Comorbidity was defined as the presence of any of: ischemic heart disease, hypertension, congestive heart disease, diabetes mellitus, peripheral vascular disease, and cerebrovascular disease. b Complication was defined as any of the following postoperative complications: atrial fibrillation, prolonged air-leak, pneumonia, reintubation, and reoperation. 74.8 (20.7), p < 0.001). The change between baseline and 2-year follow-up was clinically relevant (+12.8 score points, p < 0.001).
The RP subscale dropped from 63.6 (41.1) at baseline to 41.3 (43.6) at 6 months ( p < 0.001) and improved to 55.3 (43.1) ( p < 0.001). The changes between baseline and 6 months (-22.3 score points, p < 0.001) as well as between 6 months and 2 years follow-up (+14 score points, p < 0.001) were clinically relevant.
Late clinically relevant changes in the SF-36 summary scores Between 6 months and 2 years, the majority of the patients reported no change or improved levels in both the PCS and MCS scores. No change was defined as a score change of less than 10%, and a clinically relevant improvement was defined as a score increase of 10% or more. An improvement in the PCS score from 6 months to 2 years was reported by 30% of the patients. No change was reported by 45%, and 25% reported a deterioration. An improvement in the MCS score was reported by 39% of the patients. No change was reported by 38%, and 23% reported a deterioration. The late clinically relevant changes in the summary scores are shown in Fig. 2 .
Late clinically relevant changes in SF-36 subscale scores
Between 6 months and 2 years, the majority of the patients reported no change or improved levels within each SF-36 subscale. No change was defined as a score change of less than 10 points, and a clinically relevant improvement was defined as a score increase of more than 10 points. The largest positive change was noted in the MH subscale. While 45% of the patients reported an improvement, 40% reported no change. The largest negative change was found in the vitality (VT) subscale, where 35% of the patients reported deterioration, 47% reported no change, and only 18% reported an improvement. Late clinically relevant changes in the SF-36 subscale scores are shown in Fig. 3 .
Late changes in quality of life stratified by sex and age
Late changes in the SF-36 PCS and MCS scores, stratified by sex and age, are shown in Table 5 .
In men, there was no change (41.3 vs 41.6) in the PCS score between 6 months and 2 years. In the MCS score, a small (3.5%) but not clinically relevant improvement was noted (45.2 vs 46.8). In women, there was no change (40.9 vs 41.2) in the PCS score between 6 months and 2 years. In the MCS score, a 7% improvement was noted (44.0 vs 47.0). Thus, there was no difference between men and women regarding the late changes in the PCS score. However, in both men and women, there was a small improvement in the MCS score. Even though the change was larger among women, it was not clinically relevant.
In young patients (age <70 years), there was no change in the PCS score (44.8 vs 44.3) or the MCS score (44.5 vs 46.1) between 6 months and 2 years. However, in the old patients (age >70 years), a small deterioration (3.4%) was noted in the PCS score (37.9 vs 37.6). By contrast, there was a clinically significant 
DISCUSSION
In this population-based prospective study of patients undergoing lung surgery for lung cancer, we found that the physical aspect of health-related quality of life was similar at 6 months and 2 years after surgery. Interestingly, during the same period, a moderate improvement was noted in the mental aspect. Despite a continuous improvement in the mental domain, both physical and mental health-related quality of life of the study population were worse compared to an age-and gendermatched reference population 2 years after surgery. The prospective population-based design of our study, together with a high response rate, offers a reduced risk of selection bias and increase in the external validity.
Furthermore, we performed an analysis of possible differences between the study population and the nonresponders and found that the groups were very similar regarding important baseline characteristics.
Adjuvant chemotherapy was more common among nonresponders (23.5% vs 38.6%, p = 0.017). Because adjuvant therapy is associated with symptoms capable of affecting health-related quality of life, our results may be inflated due to a larger nonresponse rate among patients with adjuvant chemotherapy. However, in the prospective study by Handy et al. [6] , adjuvant therapy was not found to adversely affect postoperative quality of life at follow-up 6 months after surgery. Moreover, it was recently shown that patients who had surgery and adjuvant chemotherapy reported equivalent EQ-5D utility score compared to patients receiving surgery alone [14] . In a future, adequately sized, study it would be interesting to analyze the effect of adjuvant therapy on quality of life after lung surgery.
The aim of the study was to examine the long-term healthrelated quality of life after lung surgery. To facilitate comparison with previous studies [6, 7] and to allow sufficient time for patients to recuperate from the early postoperative strain, the first follow-up was carried out 6 months after surgery. Because failure to cure lung cancer by surgical resection generally results in recurrence within 2 years, it has been proposed that a followup time of 2 years would give the most useful information for the patient [15] .
Our results showed that the mean PCS score was unchanged and the mean MCS score improved moderately between 6 months and 2 years. By a different analytical approach, describing clinically relevant changes rather than statistically significant differences, we found that only 25% of the study population actually reported a clinically relevant deterioration in the physical and mental aspects of health-related quality of life between 6 months and 2 years after surgery. The majority of the patients reported no change or improved levels in both the PCS and MCS scores. We defined a clinically relevant improvement as a summary score increase of 10% or more. However, there is no universal method for defining the clinical significance or even the minimally important difference of quality-of-life data [16] . One way of defining a clinically significant change in quality of life is a difference score that is large enough to have an implication for the patient's treatment or care [17] . A definition of a clinically relevant difference analogous to ours has recently been used in a large randomized trial [18] .
In a previous report [19] , we found no evidence of a significant difference between men and women regarding changes in physical or mental health-related quality of life during the first 6 months after surgery. Nor did we observe any difference between men and women regarding the changes in health-related quality of life during long-term follow-up.
In a recent article, we reported that both old and young patients experienced deterioration in physical and mental health-related quality of life at 6 months; however, the change in quality of life did not differ significantly between the groups [20] . Our long-term data showed that the PCS score in both young and old patients remained unchanged between 6 months and 2 years. By contrast, there was a clinically significant improvement among old patients in the MCS score. This improvement was not found among young patients. Other studies examining the effect of age on quality of life after lung surgery provide mixed results, and interpretation is complicated due to the use of different quality-of-life instruments [5, 14, 21] .
Schulte et al. found that physical function, pain, and dyspnea remained significantly impaired 2 years after surgery, but the other quality-of-life indicators approached baseline after an initial postoperative decrease [22] . Moreover, Kenny et al. found that even disease-free survivors continued to report functional limitations and symptoms 2 years after surgery, but stable or improved emotional functioning at 2 years after surgery [23] . A similar sustained decrease in health-related quality of life after 2 years was reported by Ilonen et al. [24] .
Available prospective long-term data [22] [23] [24] on quality of life after lung surgery seem to be consistent and present evidence for long-lasting limitations in the physical domain, but a partial recovery of mental or emotional capabilities. In our prospective population-based cohort study, we found an early decrease in the physical aspect of health-related quality of life which was still present 2 years after surgery while a moderate improvement was noted in the mental aspect. Our results support the conclusions from previous studies.
LIMITATIONS OF THE STUDY
For practical reasons, we were not able to include all patients who underwent lung surgery at our department. We believe that the risk of introducing bias was low. Another limitation is the use of only one quality-of-life questionnaire. An additional instrument could perhaps offer information not covered by the SF-36. A low-response rate may impair the validity of a study, but we had a response rate of 85% at 6 months and 95% at 2 years.
CONCLUSIONS
In this prospective population-based cohort study, we found an early decrease in the physical aspect of health-related quality of life at 6 months after surgery, which was still present at 2 years of follow-up. A moderate clinically relevant improvement was noted in the mental aspect at 6 months and further improvement was reported at 2 years of follow-up. Our results support the conclusions from previous studies.
